Sergliflozin etabonate

Sergliflozin etabonate

Systematic (IUPAC) name
2-(4-methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	408504-26-7 Y
ATC code	none
PubChem	CID: 9824918
IUPHAR/BPS	4587
ChemSpider	21234810 N
ChEMBL	CHEMBL450044 N
Chemical data
Formula	C23H28O9
Molecular mass	448.463 g/mol
SMILES CCOC(=O)OCC1C(C(C(C(O1)Oc2ccccc2Cc3ccc(cc3)OC)O)O)O
InChI InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3 N Key:QLXKHBNJTPICNF-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Sergliflozin etabonate (INN/USAN, codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.

Method of action

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.

Chemistry

Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.

Sergliflozin